10
Participants
Start Date
October 31, 2012
Primary Completion Date
September 30, 2016
Study Completion Date
November 30, 2020
Treatment with in vitro expanded haploidentical NK cells
10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at \<1x10e5/kg
University Hospital, Basel
University Hospital, Basel, Switzerland
OTHER